SAN DIEGO, CA -- (Marketwired) -- 07/03/13 -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in…
Continue ReadingTag: lipidomics
Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP
Patents Provide Coverage for Lpath-s Anti-S1P Antibody in the Treatment of a Wide Variety of Hyperproliferative…
Continue ReadingLpath to Present at ROTH Capital Partners 25th Annual Growth Stock Conference on March 19, 2013
SAN DIEGO, CA -- (Marketwire) -- 03/12/13 -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in…
Continue ReadingLpath Signs Collaboration and License Agreement With Provista Diagnostics to Develop Cancer Diagnostics
SAN DIEGO, CA -- (Marketwire) -- 03/06/13 -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in…
Continue ReadingLpath to Present Data at Arrowhead-s 3rd Annual Traumatic Brain Injury Conference on March 7, 2013
SAN DIEGO, CA -- (Marketwire) -- 02/25/13 -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in…
Continue ReadingLpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development
SAN DIEGO, CA -- (Marketwire) -- 02/13/13 -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in…
Continue ReadingLpath Sets Investor Update Conference Call for Thursday, January 3, 2013 at 4:30 p.m. ET
SAN DIEGO, CA -- (Marketwire) -- 12/26/12 -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in…
Continue ReadingLpath Announces Pricing of Public Offering of Common Stock
SAN DIEGO, CA -- (Marketwire) -- 12/14/12 -- Lpath, Inc. (NASDAQ: LPTN), today announced that it…
Continue ReadingLpath Announces Proposed Public Offering of Common Stock
SAN DIEGO, CA -- (Marketwire) -- 12/13/12 -- Lpath, Inc. (NASDAQ: LPTN) today announced that it…
Continue ReadingLpath Granted Key European Patent Related to iSONEP Drug Program
New Patent Provides Coverage for Lpath-s Anti-S1P Antibody, Sonepcizumab, in the Treatment of a Wide Variety…
Continue Reading